Atosiban 98% Cas No.90779-69-4
Specification: ≥98%
CAS No.: 90779-69-4
Molecular Formula: C₄₃H₆₇N₁₁O₁₂S₂
Molecular Weight: 994.19
Analytical Method: HPLC
Active Ingredient: Atosiban Acetate
Product Characteristics: White to off-white crystalline powder
Product Packaging: Various packaging specifications available (mg, g, kg), customizable Storage Condition: Recommended to be stored sealed, protected from light, and lyophilized at -20°C
Shelf Life: 24 months
Declaration of Use: This product is intended for industrial use or scientific research only.

Atosiban Acetate API (CAS 90779-69-4)
High-Purity Peptide Manufacturer | Xi'an Tihealth
Pharmaceutical Grade Peptides for R&D and Commercial Formulation
Atosiban Acetate (CAS No. 90779-69-4) is a synthetic nonapeptide and a highly specific competitive antagonist of oxytocin and vasopressin receptors. It is clinically essential for the management of premature labor (tocolysis). As a specialized peptide API supplier, Xi'an Tihealth Biotechnology Co., Ltd. strictly adheres to rigorous solid-phase peptide synthesis (SPPS) and liquid-phase purification protocols. Our Atosiban Acetate powder is engineered with an exceptional purity profile (≥99.0%), specifically designed to meet the stringent requirements of global pharmaceutical manufacturers for sterile injectable formulations.
Technical Data Sheet (TDS) & Core Specifications
| Parameter | Specification Limit (USP/EP Standards) | Typical Batch Result |
|---|---|---|
| Sequence | c[Mpa-D-Tyr(Et)-Ile-Thr-Asn-Cys]-Pro-Orn-Gly-NH2 | Confirmed by MS |
| Peptide Purity (HPLC) | ≥ 99.0% | 99.45% |
| Trifluoroacetic Acid (TFA) | ≤ 0.5% (Strictly Controlled) | 0.12% |
| Bacterial Endotoxins | ≤ 0.5 EU/mg (Injection Grade) | < 0.1 EU/mg |
| Water Content (Karl Fischer) | ≤ 8.0% | 3.8% |
| Specific Rotation | -64.0° to -74.0° | -69.5° |
*Detailed HPLC Chromatograms and MS Characterization reports are available upon corporate request for DMF support.
Advanced R&D Support & Formulation Compatibility

The synthesis of nonapeptides containing disulfide bridges, such as Atosiban Acetate, requires sophisticated control over oxidative cyclization to prevent dimerization. Xi'an Tihealth utilizes proprietary purification technologies to address these critical API formulation challenges:
- Ultra-Low Residual Solvents: Advanced lyophilization cycles ensure that TFA and organic solvent residues are significantly below regulatory thresholds, enhancing the stability of the final reconstituted injectable.
- Precise Counter-Ion Exchange: We offer customized acetate content control to ensure the ideal physiological pH compatibility during your formulation process.
- GMP-Aligned Traceability: All batches are produced in facilities following ISO 9001:2015 and GMP-aligned quality systems, facilitating seamless DMF filings and regulatory audits.
Regulatory Notice: This product is classified as an Active Pharmaceutical Ingredient (API). It is strictly intended for B2B industrial formulation, laboratory research, and pharmaceutical development only. All applications must comply with respective national regulations (e.g., FDA, EMA, NMPA).
Frequently Asked Questions (FAQ)
What is the recommended storage condition for Atosiban Acetate API?Hot Tags: atosiban 98% cas no.90779-69-4, China atosiban 98% cas no.90779-69-4 manufacturers, suppliers, factory, hialuronato de sodio hialuronato sodico sodium hyaluronate, , ,
You Might Also Like
Send Inquiry








